Comparison between nasal and intravenous desmopressin for the treatment of aminosalicylic acid-induced platelet dysfunction

Schulz-Stübner, Sebastian; Zielske, D.; Rossaint, Rolf

doi:10.1097/00003643-200209000-00005

Cited by 6 publications

(2 citation statements)

References 16 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…In solchen Fäl-len muss mit erhöhten Blutungskomplikationen und postoperativer Morbidität gerechnet werden [22]. Zur Verminderung schwerer perioperativer Blutungen bei dualer Plättchenhemmung kann es nötig werden, neben Allgemeinmaß-nahmen zur Stabilisierung der plasmatischen Gerinnung Thrombozytenkonzentrate und Desmopressin (0,03 µg/kg Kör-pergewicht) zu verabreichen [24]. Bei dringenden Operationen (keine Notfalleingriffe) mit hohem Risiko eines kardiovaskulären Ereignisses kann es sinnvoll sein, ein Bridgingschema zur Vermeidung einer dualen Plättchenhem-mung unmittelbar perioperativ durchzuführen, um die Blutungskomplikationen und die kardiale Morbidität so gering wie möglich zu halten (.…”

Section: Perioperative üBerbrückungs-therapie ("Bridging")unclassified

Thrombozytenfunktionshemmung nach koronarer Stentimplantation: Bedeutung in der Endoprothetik

et al. 2012

View full text Add to dashboard Cite

Coronary stenting is an effective treatment for reopening atherosclerotic occlusions of coronary arteries. Depending on the manifestation of coronary artery disease (stable CAD or acute coronary syndrome) and on the type of implanted stent, dual antiplatelet therapy is recommended for a period of 4 weeks to 12 months. In this period total joint replacement is associated with high blood loss and high perioperative morbidity. Therefore antiplatelet therapy is often discontinued and replaced by higher dosages of heparin for prophylactic anticoagulation. However, with this treatment regimen protection of the stent is doubtful and there is a high risk of stent thrombosis with myocardial infarction. The surgery should be scheduled after the dual antiplatelet therapy is replaced by lifelong aspirin therapy. On the other hand, if surgery cannot be postponed perioperative bridging of dual antiplatelet therapy can be conducted to minimize bleeding complications with the best possible stent protection. Lifelong therapy with aspirin should not be discontinued in any case.

show abstract

Section: Perioperative üBerbrückungs-therapie ("Bridging")unclassified

Thrombozytenfunktionshemmung nach koronarer Stentimplantation: Bedeutung in der Endoprothetik

et al. 2012

View full text Add to dashboard Cite

show abstract

“…In regard to the therapeutic management of patients with SDH on aspirin I would like to add the option of platelet function enhancement with the application of desmopressin (DDAVP). Given at a dose of 0.03 lg/kg body weight intravenously or intranasally a peak effect with almost normalization of PFA values can be observed within 30 min lasting for about 4 h in healthy volunteers [2]. Especially when immediate lab results for platelet function are not available empiric treatment for surgery might be warranted for patients on aspirin to provide an optimal time window for surgical evacuation of the hematoma and prevention of rebleeding.…”

mentioning

confidence: 99%